Search

Abstract Background Early and accurate diagnosis of dengue infection is essential for control of disease outbreaks. Recently, the dengue virus non-structural antigen 1 (NS1), a conserved and secreted glycoprotein, has been used as a marker for early diagnosis of dengue with convenience and cost-effectiveness. Serological tests of dengue IgM and IgG antibodies are still the most widely used for diagnosis of dengue. In order to assess combined diagnostic value of these tests, we study the kinetic profiles of circulating NS1, dengue IgM and IgG antibodies over the course of the disease by using an in-house dengue type 1 (DENV1) specific NS1 capture ELISA and the commercial Panbio Dengue IgM and IgG capture ELISAs. Results A panel of 313 acute-and early convalescent-phase serum specimens from 140 DENV1 primary infected patients during an outbreak of dengue in Guangzhou, China, in 2006 were studied. Dengue NS1 presented high levels in acute-phase serum samples. It was detectable as early as day 1 of illness, and up to 14 day after onset. The sensitivity of NS1 detection was ranged from 81.8% to 91.1% with samples taken during the first 7 days. Anti-dengue IgM antibody was detectable on the third day of onset with the positive rate of 42.9%, and rapidly increasing to 100% by day 8 of illness. Anti-dengue IgG antibody was detectable on the fifth day of onset with low level at the first week of onset, and slowly increasing to 100% by day 15 of illness. Combining the results of NS1 and IgM antibody detection allowed positive diagnosis in 96.9% -100% for samples taken after day 3 of onset. Conclusions Dengue NS1 detection might shorten the window period by first few days of illness. A combination of dengue NS1 antigen and IgM antibody testing facilitates enhanced diagnosis rates. The procedures should be suitable for developing countries where dengue is endemic.

Dengue virus (DENV) envelope [E] protein is the major surface protein of the virions that indued neutralizing antibodies. The domain III of envelope protein (EDIII) is an immunogenic region that holds potential for the development of vaccines; however, the epitopes of DENV EDIII, especially neutralizing B-cell linear epitopes, have not been comprehensively mapped. We mapped neutralizing B-cell linear epitopes on DENV-1 EDIII using 27 monoclonal antibodies against DENV-1 EDIII proteins from mice immunized with the DENV-1 EDIII. Epitope recognition analysis was performed using two set of sequential overlapping peptides (16m and 12m) that spanned the entire EDIII protein from DENV-1, respectively. This strategy identified a DENV-1 type- specific and a group-specific neutralizing epitope, which were highly conserved among isolates of DENV-1 and the four DENV serotypes and located at two regions from DENV-1 E, namely amino acid residues 309-320 and 381-392(aa 309-320 and 381-392), respectively. aa310 -319(310KEVAETQHGT319)was similar among the four DENV serotypes and contact residues on aa 309 -320 from E protein were defined and found that substitution of residues E309 , V312, A313 and V320 in DENV-2, -3, -4 isolates were antigenically silent. We also identified a DENV-1 type-specific strain-restricted neutralizing epitope, which was located at the region from DENV-1 E, namely amino acid residues 329-348 . These novel type- and group-specific B-cell epitopes of DENV EDIII may aid help us elucidate the dengue pathogenesis and accelerate vaccine design.

Objective: To establish a double antibody sandwich ELISA for detecting Csa2 protein in Candida albicans infection and evaluate its specificity and sensitivity., Methods: A recombinant expression vector pPIC9K-Csa2 was constructed and transformed into Pichia pastoris GS115. A large-scale expression of recombinant Csa2 protein (rCsa2) was optimized using methanol, and the protein was purified in P. pastoris expression system. New Zealand Rabbits and guinea pigs were respectively immunized with the purified rCsa2 to prepare polyclonal antisera. The double antibody sandwich ELISA was established by choosing the optimal dilution of coating antisera and detecting antisera. Different concentrations of rCsa2 and culture supernatants of C. albicans collected at different time points were used to evaluate the sensitivity of detection. The specificity of the sandwich ELISA was evaluated by detecting culture supernatants of other three Candida spp, five Aspergillus spp, Cryptococcus neoformans and Penicillium marneffei., Results: The rCsa2 protein was successfully expressed and purified. SDS-PAGE showed that its Mr was 13 300. Western blotting demonstrated that the protein bound to specific antibody. The sensitivity of the sandwich ELISA we established using the high-titer antisera was about 240 pg/mL of rCsa2, and could detect Csa2 protein in the culture supernatant of C. albicans when cultured for as early as 18 hours. There was no cross-reactivity between the culture supernatants of other 10 clinically important fungi and C. albicans., Conclusion: The double antibody sandwich ELISA for detecting Csa2 protein has been established with good sensitivity and specificity. Csa2 protein could be used as a new diagnostic marker of C. albicans infection.